King Pharmaceuticals Reports FDA Approval Of Revised Labeling Regarding Purity Of THROMBIN-JMI(R)

King Pharmaceuticals, Inc. (NYSE:KG) reported that the U.S. Food and Drug Administration (FDA) has approved revised labeling for THROMBIN-JMI® (thrombin, topical, bovine, USP) as a result of continuous enhancements the Company has made with respect to its manufacturing processes for the product. The revised labeling recognizes the capability of King’s enhanced processes to reduce Factor V light chain content to undetectable levels using currently available methodologies.

More: continued here

Filed under: Blood on January 17th, 2008